| Code | CSB-RA003996MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Avdoralimab, designed to specifically target C5AR1 (complement component 5a receptor 1), also known as CD88. C5AR1 is a G protein-coupled receptor that binds complement fragment C5a, playing a critical role in innate immune responses and inflammatory processes. Upon activation, C5AR1 triggers neutrophil chemotaxis, degranulation, and the production of pro-inflammatory mediators. Dysregulated C5AR1 signaling is implicated in numerous pathological conditions, including sepsis, acute respiratory distress syndrome (ARDS), COVID-19-associated complications, inflammatory bowel disease, and various autoimmune disorders.
Avdoralimab is a clinical-stage therapeutic antibody that blocks C5a-C5AR1 interaction, thereby modulating excessive complement activation and inflammation. This biosimilar provides researchers with a valuable tool for investigating C5AR1-mediated pathways, exploring complement system biology, and developing models of inflammatory diseases. It serves as an essential reagent for studies examining therapeutic interventions targeting the complement cascade and neutrophil-driven inflammation in preclinical research settings.
There are currently no reviews for this product.